UNSPSC 51102872: Prednisolone/sulfacetamide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.

UNSPSC 51102872 Prednisolone/sulfacetamide, a Commodity code, shows minimal alignment between its nominal scope and recent state and local procurement activity tagged under it. The code's abstract name references a specific ophthalmic pharmaceutical combination, yet recent solicitations posted under this code span naloxone procurement, direct-to-manufacturer pharmacy programs, emergency medical and first aid supplies for fire rescue operations, and multi-state generic pharmaceutical and OTC product contracts—none of which involve prednisolone/sulfacetamide formulations. State and local buyers tagging opportunities under this code are sourcing a broad range of pharmaceutical, medical supply, and pharmacy-benefit products across health departments, HHS agencies, fire rescue divisions, and cooperative purchasing alliances, suggesting the code is being used as a catch-all pharmaceutical commodity bucket rather than for the specific ophthalmic product the code nominally describes. The mismatch between code name and actual buying activity indicates this code has limited utility for tracking a specific product line and may reflect system-level tagging practices that do not enforce code-scope specificity.

Recent activity spans Florida (Seminole County naloxone and drug deactivation procurement posted June 30, 2026, IFB closing July 26, 2023), Texas (Texas HHS Commission RFI on direct-to-manufacturer prescriptions posted April 3, 2026), Florida again (City of Tampa Fire Department medical and first aid supplies IFB posted March 25, 2026 with estimated value $700,000.00), and a multi-state cooperative purchasing vehicle (Minnesota MMCAP generic pharmaceuticals and OTC products RFP posted January 20, 2026, response due March 26, 2026, covering Minnesota, Oregon, and participating jurisdictions). The Seminole County and Tampa solicitations target specific product categories and service levels; the MMCAP RFP reaches the broadest market through authorized wholesalers with a two-year contract term and multi-award structure. Given the code's misalignment with recent buying activity, treat this code as low-priority for business development unless your firm manufactures prednisolone/sulfacetamide formulations specifically—the recent opportunities bear little relevance to that product scope.